Vaccine against cervical cancer: study proves effectiveness of vaccine against HPV virus-Human Papilloma Virus and thus indirectly against development cervical cancer. Article update 1 February 2012

14 april 2005 "source: The Lancet: Human Papillomavirus Quadrivalent Vaccine May Be Effective

A double-blind randomized study-277 again proves young women (average age, 20.2) quadrivalent HPV vaccine received approx. 1.5 years, and 275 women (average age, 20.0 years) were given a placebo-circa. 1.7 years that a vaccine against HPV infection may be a very good work. 90% of women in a study at more than 200 women remained free of these four HPV viruses which are almost always the source of novice cervical cancer

Results: compared with women who had received a placebo vaccine administered the women who got 90% reduction of infections or illness caused by the HPV virus 6, 11, 16 or 18. (95% confidence interval, 71%-97%; P< .0001).="" alle="" drie="" de="" vrouwen="" die="" externe="" genitale="" wondejes="" kregen="" en="" alle="" drie="" de="" vrouwen="" die="" eerste="" verschijnselen="" van="" baarmoederhalskanker="" ontwikkelden="" kwamen="" uit="" de="" controlegroep="" met="" placebo.="" het="" vaccin="" was="" 100%="" effectief="" tegen="" eerste="" stadia="" van="" baarmoederhalskanker="" en="" genitale="" wrattten="" geassocierd="" met="" genoemde="" vier="" hpv="" virustypes.="" er="" werden="" geen="" negatieve="" effecten="" van="" het="" vaccin="" gevonden="" of="" ervaren.="" de="" onderzoekers="" concluderen="" dat="" een="" vaccin="" dat="" de="" hpv="" virussen="" 6,="" 11,="" 16="" en="" 18="" bestrijdt,="" daarmee="" ook="" de="" genitale="" wratten="" en="" voorstadia="" van="" baarmoederhalskanker="" veroorzaakt="" door="" die="" vier="" virussen="" effectief="" kan="">

April 7, 2005 — Human papillomavirus (HPV) quadrivalent vaccine may be effective against persistent infection or disease, according to the results of a randomized, double-blind study published in The Lancet Oncology online April 7. A large study is underway.

"In the developed world, full implementation of cervical-cancer screening has substantially shifted the burden of HPV infection from cervical cancer mortality to management or precancerous lesions," lead author Luisa l. Villa, PhD, from Ludwig Institute for Cancer Research in Sao Paulo, Brazil, says in a news release. "In these countries, in addition to further reduction in incidence of cervical cancer, HPV vaccination might decrease the medical, psychological, universal, and economic costs associated with the management of abnormalities detected by screening."
This phase 2 study tested the efficacy of a quadrivalent prophylactic HPV types 16 and 18 vaccine targeting, which are associated with cervical cancers, and 70% or types 6 and 11, which are associated with 90% or genital warts. The quadrivalent, L1 virus-like-particle (VLP) vaccine consisted of 20 µg type 6, 40 µg type 11, 40 µg type 16, and 20 µg type 18.
In this trial, Dr. Villa and colleagues randomized 277 young women (mean age, 20.2 ± 1.7 years) quadrivalent HPV vaccine to receive, and 275 women (mean age, 20.0 ± 1.7 years) were randomized to receive one of two placebo preparations at day 1, month 2, and month 6.Participants had regular gynecological examinations, sampling for HPV DNA testing for cervicovaginal serum antibodies to HPV, and Papanicolaou testing for 36 months.
Analysis was primarily per protocol, and the primary outcome was the combined incidence of infection with HPV 6, 11, 16, or 18, or cervical or external genital HPV infection, HPV disease, defined as persistent detection intraepithelial neoplasia at the last recorded visit, cervical, cervical cancer, or external genital lesions caused by the HPV types in the vaccine.
Compared with women randomized to receive placebo, those randomized to receive vaccine had a 90% decrease in combined incidence of persistent infection or disease with HPV 6, 11, 16, or 18 (95% confidence interval, 71%-97%; P< .0001).="" all="" three="" women="" with="" external="" genital="" lesions="" and="" all="" three="" with="" cervical="" intraepithelial="" neoplasia="" were="" in="" the="" placebo="" group.="" the="" vaccine="" was="" 100%="" effective="" against="" precancerous="" cervical="" lesions="" and="" genital="" warts="" associated="" with="" these="" four="" hpv="" types,="" and="" there="" were="" no="" serious="" adverse="" events="" related="" to="" the="" vaccine.="" the="" authors="" suggest="" that="" a="" vaccine="" targeting="" hpv="" types="" 6,="" 11,="" 16,="" 18="" could="" substantially="" reduce="" the="" acquisition="" of="" infection="" and="" clinical="" disease="" caused="" by="" common="" hpv="" types.="">
Study limitations include lack of power to assess vaccine efficacy for the disease end points or for each HPV type separately, and duration of follow-up limited to three years.
"Inclusion of HPV 6 and 11 in a vaccine could also diminish the incidence of genital warts," Dr. Villa says. "In developing countries that have not implemented screening programs for cervical cancer, HPV vaccine could substantially reduce the incidence a universal or the disease."
Merck, the developer of the quadrivalent HPV vaccine, funded this clinical trial, employs 10 or its authors, and has financial arrangements with several other authors.
Lancet Oncol. Published online April 7, 2005

. Reviewed by Gary d. Vogin,MD